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There is growing evidence that aberrant gene expression in cancer is linked to epigenetic deregulation like
promoter cytosine methylation in CpG-islands. In this issue of Cancer Cell, Figueroa et al. show that
genome-wide promoter DNA methylation profiling reveals unique AML subgroups and methylation patterns
that are associated with clinical outcome.Acute myeloid leukemia (AML) represents
a heterogeneous group of leukemias that
differ with regard to biology, clinical
course, and prognosis. During recent
years, considerable progress has been
made in deciphering chromosomal aber-
rations, gene mutations, and disordered
gene expression that alter normal gene
function (Figure 1). Based on this
improved understanding of the molecular
biology of AML, new diagnostic and
prognostic markers have been defined
(Dohner et al., 2009). Furthermore, novel
therapeutic approaches are now being
developed that target some of the mo-
lecular lesions, including epigenetic
alterations by making use of, e.g., DNA
methyltransferase inhibitors, although
the extent and specific role of epigenetic
modifications in leukemogenesis are still
poorly understood.
Modulation of gene expression as a
result of changes in histone and DNA
modifications orchestrates key biological
processes such as differentiation, im-
printing, and silencing of large chromo-
somal domains. This type of control of
gene expression is often termed epige-
netics. It is becoming increasingly clear
that a multitude of complex and interde-
pendent epigenetic alterations collabo-
rate with genetic changes in the develop-
ment and progression of cancer (Jones
and Baylin, 2007). Particularly, the impor-
tance of aberrant promoter cytosine
methylation in CpG islands and the result-
ing gene silencing has been shown to
be involved in cancer development.
Improved insights into epigenetic control
of gene expression may become espe-cially valuable because genomic aberra-
tions underlying cancer are largely irre-
versible, but epigenetic changes have
the potential to be modulated for thera-
peutic benefit. Thus, a growing under-
standing of the linkage of genetic and
epigenetic changes that promote leuke-
mogenesis and the identification of ap-
propriate biomarkers represents a prereq-
uisite for successful epigenetics-directed
leukemia therapy.
Following early reports that demon-
strated hypermethylation of candidate
tumor suppressor genes in hematologic
malignancies, methylation-sensitive en-
zyme-based restriction landmark geno-
mic scanning (RLGS) was used as an
initial tool for widespread assessment of
altered DNA methylation. RLGS was
used to detect genes with altered patterns
of methylation in chemotherapy-sensitive,
primary refractory and relapsed AML
(Plass et al., 1999). Since then, novel
technologies, such as microarray-based
approaches, have provided increasingly
powerful means for genome-wide quanti-
tative investigation of DNA-methylation
status in leukemia, suggesting that these
approaches may identify novel disease
markers (Gebhard et al., 2006).
In this issue of Cancer Cell, Figueroa
et al. (2010) apply genome-wide promoter
DNA methylation profiling to a large cohort
of 344 newly diagnosed primary AML
samples using the recently developed
HELP (HpaII tiny fragment enrichment by
ligation-mediated PCR) assay. Following
data normalization and filtering, unsuper-
vised hierarchical clustering analysis
revealed 16 distinct methylation patternsCancer Cellthat correlate well with known cytoge-
netically defined leukemias, including
t(15;17), inv(16), t(8;21), or t(11q23) AML
subgroups. This finding was perhaps
predictable given each subset is charac-
terized by a distinct gene-expression
profile and the fusion oncogenes them-
selves may directly influence the epige-
netic machinery in hematopoietic cells,
but it is an important validation of the tech-
nology and the underlying assumption
that genome-wide DNA methylation
profiles will provide valuable insight.
Next, the authors provide valuable new
insight into AML biology by integrating
DNA methylation and gene expression to
discover newly identified, not otherwise
classified AML methylation subgroups.
In line with a previous report (Gebhard
et al., 2006), there was only a partial over-
lap of the aberrantly methylated and ex-
pressed genes in each cluster (Figueroa
et al., 2010). Figueroa and colleagues
point out that this may be in part due to
silencing of critical genes that lead to
widespread changes in gene expression.
Furthermore, the fact that not all methyl-
ated genes are repressed at the expres-
sion level suggests that (1) aberrant gene
expression in leukemia is influenced by
many factors in addition to DNA methyla-
tion and (2) promoter DNA-methylation-
associated transcriptional repression
can either be overcome by other mecha-
nisms or is active only at certain pro-
moters. Interestingly, the concordantly
regulated genes in each subgroup were
significantly enriched for members of
distinct pathways, such as p53 signaling
and DNA-damage response, thereby17, January 19, 2010 ª2010 Elsevier Inc. 1
Figure 1. A Decade of ‘‘-omics’’ Research in AML
At the beginning of this decade, microarray-based gene expression profiling studies began providing new
insight into leukemia pathogenesis. Since then, novel SNP microarray and sequencing-based genomics
studies have unraveled novel findings, and now, genome-wide epigenomics promises to provide a deeper
understanding of leukemia. Proteomics approaches are currently also under development (picture kindly
provided by Drs. F. Heidel and T. Fischer, University of Magdeburg, Germany). Future efforts will aim
toward integrated data analyses, thereby leading to a more comprehensive view of the biology of this
disease, a prerequisite for refined AML classification and improved patient management.
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Previewspointing to distinct biological processes
underlying the respective methylation-
defined clusters that can now be as-
sessed experimentally.
Strikingly, as there is known molecular
heterogeneity with regard to secondary
molecular aberrations influencing sig-
naling pathways, such as CBL, FLT3,
JAK2, KIT, KRAS, and NRAS mutations
in core-binding factor leukemias, the rela-
tive uniformity of DNA-methylation
profiles in this leukemia subset suggests
the signaling mutations do not have a
dominant impact on DNA methylation
profiles. However, the primary genetic
events contributing to impaired hemato-
poietic differentiation as defined by the
WHO subgroup ‘‘AML with recurrent
genetic abnormalities,’’ including NPM1
or CEBPA gene mutations, seem to have
the greatest impact on the epigenetic
profiles. In accordance, Figueroa and
colleagues could not define a methylation
pattern associated with FLT3 aberrations
(FLT3-ITD) (Figueroa et al., 2010). Thus,
the newly discovered, methylation-
pattern-defined AML subgroups might
lead the way to yet unknown leukemia-
‘‘initiating’’ events. For example, does
the cytogenetic heterogeneity in the2 Cancer Cell 17, January 19, 2010 ª2010 Elnewly identified cluster 2 reflect an epige-
nomic profile associated with a yet un-
known mutation, or do multiple mutations
result in the deregulation of an identical
pathomechanism, thereby leading to
a unique DNA methylation profile?
Similarly, the presence of a DNA meth-
ylation pattern ‘‘common’’ to most AML
cases raises interesting issues: first,
does leukemogenesis require silencing
of a common set of genes, which are tar-
geted by different primary events?
Second, is this common methylation
pattern caused by a leukemia-permissive
event, that is common to all leukemia
subgroups? Or third, does this reflect a
remainder of the cell of origin methylation
profile in which the leukemic transforma-
tion occurred? Finally, similar to a recent
study that used MALDI-TOF matrix-assis-
ted laser desorption/ionization time-of-
flight mass-spectrometry to quantitatively
screen the DNA-methylation status of 92
genomic regions in 256 AML samples
and define a methylation-based outcome
predictor for patient survival (Bullinger
et al., 2009), the authors could build a
robust DNA-methylation-based outcome
predictor that provided novel information
independent from known genomicsevier Inc.markers (Figueroa et al., 2010). These
large scale epigenetic analyses in AML
support the use of genomic methylation
markers for improved molecular classifi-
cation and prognostication in adult AML.
The studies performed by Figueroa et al.
provide an important initial glimpse into
genome-wide DNA methylation profiles in
AML through assessment of CpG island
promoter methylation. Future investiga-
tions will assess whether regions of DNA
methylation beyond promoter-associated
CpG islands are important for disease.
Recent genome-wide next generation
sequencing studies demonstrated that
methylation of CpG sites represent
dynamic epigenetic marks that undergo
extensive changes during cellular differen-
tiation, particularly in regulatory regions
outside of core promoters (Meissner
et al., 2008), and initial single-base-resolu-
tion maps of DNA methylation demon-
strate that methylation in non-CpG
contexts might play an important role in
undifferentiated cells (Lister et al., 2009).
Furthermore, assessment of other chro-
matin modifications that play a role in
leukemia development will likely provide
insight (Neff and Armstrong, 2009). Fore-
most among theseare thecovalenthistone
modifications that cancontrol geneactivity
as, e.g., ectopic histone methylation of
specific lysine residues which are associ-
ated with MLL-fusion driven gene expres-
sion in leukemia (Krivtsov et al., 2008).
The study by Figueroa and colleagues
provides an optimal starting point for future
efforts that will aim to extend epigenetic
analysis in AML. This line of studies will
further clarify the mechanisms underlying
deregulated gene expression in leukemia
and further refine prognostic markers
which should result in improved patient
management and outcome.REFERENCES
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miR-15a andmiR-16-1 were the first microRNAs linked to cancer because their genes are commonly deleted
in human chronic lymphocytic leukemia (CLL). In this issue of Cancer Cell, Klein and coworkers show that
deleting a region with these genes in mouse provides a faithful model for human CLL.Chronic lymphocytic leukemia is the most
frequent leukemia of adults in the Western
world. Loss of 13q14.3 distal to the retino-
blastoma locus is the most common chro-
mosome aberration in CLL, which is pre-
sented in the majority of cases (Do¨hner
et al., 2000). Studies of clonal evolution
in CLL indicated that heterozygous dele-
tion of 13q14 is an early event, whereas
deletion of the second copy of this region
occurs at a later time point at a lower
frequency (Stilgenbauer et al., 2007).
Mutation analysis of protein-coding genes
in this region revealed no inactivation of
candidate genes. However, a complex
epigenetic regulatory tumor-suppressor
mechanism that would control the expres-
sionof the entire region and would account
also for cases without 13q14 deletion has
been proposed (Mertens et al., 2006).
Deletions at 13q14 also occur at high
frequencies in other lymphomas and solid
tumors, such as mantle cell lymphoma,
multiple myeloma, and carcinoma of the
prostate and the lung, suggesting a major
tumor-suppressor mechanism mediated
by this chromosome region.
Calin and coworkers were the first to
show that 13q14 deletion in CLL is associ-ated with downregulation of miR-15a and
miR-16-1, whose genes cluster in the
minimally deleted region (MDR) within
13q14 (Calin et al., 2002). This was the
very first link between miRNAs and
cancer. Because each miRNA is expected
to regulate the expression of hundreds
of different genes, several studies have
been carried out to identify the targets of
miR-15a and miR-16-1 (e.g., Calin et al.,
2008). Because the current algorithms
for predicting targets via sequence simi-
larities are imperfect and the effects of
miRNA level changes measured in vitro
are highly dependent on cell systems
used, the physiological relevance of
some of the published targets remains
controversial.
Klein and coworkers now report on the
conclusive functional test of relevant
13q14 genes in mouse models (Klein
et al., 2010). The MDR in 13q14 contains
the noncoding RNA gene DLEU2 with
the miR-15a and miR-16-1 cluster in its
intron 4. Klein and coworkers generated
sophisticated mouse models that have
either deletion of DLEU2 together with
both miRNA genes (MDR deleted) or dele-
tion of the two miRNA genes only. After 15to 18 months, about 5% of the animals
displayed monoclonal B cell lymphocy-
tosis (MBL), which is a possible precursor
to CLL. More importantly, 1/5 of the
MDR-deleted and 1/8 of the miR-15a/
16-1-deleted mice developed CLL or the
related small cell lymphocytic leukemia.
In addition, 9% of the MDR-deleted and
2% of the miR-15a/16-1-deleted animals
developed a phenotype reminiscent of
human diffuse large B cell lymphoma
(DLBCL), a disease known to progress
from CLL at low frequency. Thus, the
deletion of the MDR caused B cell lym-
phoproliferative disorders, nicely recapit-
ulating the spectrum of human CLL
phenotypes.
Notably, the MDR-deleted mice died
significantly earlier than did their wild-
type littermates whereas miR-15a/16-1
deletion alone did not result in survival
differences. Thus, although both MDR-
deleted and miR-15/16-deleted mice
develop an indolent disease reminiscent
of CLL, there is at least one genetic
element within the MDR other than miR-
15a/16-1 that modulates the aggressive-
ness of the disease. DLEU2 and the first
exon of DLEU1 are the only known17, January 19, 2010 ª2010 Elsevier Inc. 3
